SPIA
SLN

Steward Partners Investment Advisory’s Silence Therapeutics SLN Stock Holding History

Steward Partners Investment Advisory’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527 Hold
100
– – ﹤0.01% 4258
2025
Q4 		$608 Hold
100
– – ﹤0.01% 4136
2025
Q3 		$519 Hold
100
– – ﹤0.01% 4117
2025
Q2 		$580 Hold
100
– – ﹤0.01% 3949
2025
Q1 		$282 Hold
100
– – ﹤0.01% 3899
2024
Q4 		$688 Hold
100
– – ﹤0.01% 3812
2024
Q3 		$1.82K Hold
100
– – ﹤0.01% 3450
2024
Q2 		$1.9K Hold
100
– – ﹤0.01% 3292
2024
Q1 		$2.16K Hold
100
– – ﹤0.01% 3277
2023
Q4 		$1.74K Hold
100
– – ﹤0.01% 3227
2023
Q3 		$982 Hold
100
– – ﹤0.01% 3196
2023
Q2 		$550 Hold
100
– – ﹤0.01% 3186
2023
Q1 		$620 Hold
100
– – ﹤0.01% 3160
2022
Q4 		$1.52K Hold
100
– – ﹤0.01% 3071
2022
Q3 		$1K Hold
100
– – ﹤0.01% 3169
2022
Q2 		$1K Hold
100
– – ﹤0.01% 3162
2022
Q1 		$2K Hold
100
– – ﹤0.01% 3112
2021
Q4 		$2K Buy
+100
New +$2.31K ﹤0.01% 3033

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Steward Partners Investment Advisory's SLN Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Silence Therapeutics (SLN) position steady in Q1 2026 at 100 shares worth $527. The position accounts for ﹤0.01% of the portfolio, ranked #4258.

Steward Partners Investment Advisory first reported a position in SLN in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.16K in Q1 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Steward Partners Investment Advisory held 100 shares of Silence Therapeutics worth $527 as of Q1 2026.
  • Steward Partners Investment Advisory left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4258 holding.
  • Steward Partners Investment Advisory first reported a position in Silence Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Steward Partners Investment Advisory's Silence Therapeutics position peaked at $2.16K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.